Urinary Biomarkers Indicative of Apoptosis and Acute Kidney Injury in the Critically Ill

Show full item record



Permalink

http://hdl.handle.net/10138/161108

Citation

Vaara , S T , Lakkisto , P , Immonen , K , Tikkanen , I , Ala-Kokko , T , Pettila , V & FINNAKI Study Grp 2016 , ' Urinary Biomarkers Indicative of Apoptosis and Acute Kidney Injury in the Critically Ill ' PLoS One , vol. 11 , no. 2 , 0149956 . DOI: 10.1371/journal.pone.0149956

Title: Urinary Biomarkers Indicative of Apoptosis and Acute Kidney Injury in the Critically Ill
Author: Vaara, Suvi T.; Lakkisto, Paivi; Immonen, Katariina; Tikkanen, Ilkka; Ala-Kokko, Tero; Pettila, Ville; FINNAKI Study Grp
Contributor: University of Helsinki, Department of Diagnostics and Therapeutics
University of Helsinki, Department of Clinical Chemistry and Hematology
University of Helsinki, Clinicum
University of Helsinki, Department of Diagnostics and Therapeutics
Date: 2016-02-26
Language: eng
Number of pages: 13
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/161108
Abstract: Background Apoptosis is a key mechanism involved in ischemic acute kidney injury (AKI), but its role in septic AKI is controversial. Biomarkers indicative of apoptosis could potentially detect developing AKI prior to its clinical diagnosis. Methods As a part of the multicenter, observational FINNAKI study, we performed a pilot study among critically ill patients who developed AKI (n = 30) matched to critically ill patients without AKI (n = 30). We explored the urine and plasma levels of cytokeratin-18 neoepitope M30 (CK-18 M30), cell-free DNA, and heat shock protein 70 (HSP70) at intensive care unit (ICU) admission and 24h thereafter, before the clinical diagnosis of AKI defined by the Kidney Disease: Improving Global Outcomes - creatinine and urine output criteria. Furthermore, we performed a validation study in 197 consecutive patients in the FINNAKI cohort and analyzed the urine sample at ICU admission for CK-18 M30 levels. Results In the pilot study, the urine or plasma levels of measured biomarkers at ICU admission, at 24h, or their maximum value did not differ significantly between AKI and non-AKI patients. Among 20 AKI patients without severe sepsis, the urine CK-18 M30 levels were significantly higher at 24h (median 116.0, IQR [32.3-233.0] U/L) than among those 20 patients who did not develop AKI (46.0 [0.0-54.0] U/L), P = 0.020. Neither urine cell-free DNA nor HSP70 levels significantly differed between AKI and non-AKI patients regardless of the presence of severe sepsis. In the validation study, urine CK-18 M30 level at ICU admission was not significantly higher among patients developing AKI compared to non-AKI patients regardless of the presence of severe sepsis or CKD. Conclusions Our findings do not support that apoptosis detected with CK-18 M30 level would be useful in assessing the development of AKI in the critically ill. Urine HSP or cell-free DNA levels did not differ between AKI and non-AKI patients.
Subject: ACUTE-RENAL-FAILURE
CELL-FREE DNA
SEVERE SEPSIS
MORTALITY
DYSFUNCTION
MECHANISMS
MARKER
SERUM
SHOCK
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
journal.pone.0149956.pdf 299.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record